News & Investment Information
THE MEDICINES COMPANY SIGNS AGREEMENT TO ACQUIRE PROFIBRIX
Affirms The Medicines Company’s presence in surgical hemostasis
ProFibrix lead product Fibrocaps expected to deliver Phase 3 data third quarter 2013
Highlights The Medicines Company’s long term commitment to recombinant proteins
Parsippany, NJ, Leiden, the Netherlands and Seattle, WA, June 4, 2013— The Medicines Company (NASDAQ: MDCO) and ProFibrix B.V. today announced an agreement for The Medicines Company to purchase all of the outstanding capital stock of ProFibrix B.V. subject to...
ProFibrix Completes Patient Enrolment in Pivotal Phase III with FibrocapsTM and Reports Positive Feedback from Surgical Community
Company remains on track for 2013 filings in US and EuropeLeiden, The Netherlands and Seattle, WA, April 4, 2013 - ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced that the company has completed enrolment of its pivotal Phase III clinical trial...
ProFibrix Phase III Trial with FibrocapsTM (FINISH-3)
Passes Important Safety Milestone & Almost Completes Enrolment
Leiden, The Netherlands and Seattle, WA, February 13, 2013 - ProFibrix B.V., the leader in next generation hemostatics, today announced that the Data Monitoring Committee (DMC) of the FINISH-3 trial of Fibrocaps unanimously...
ProFibrix Passes Halfway Mark of Patient Enrolment in Pivotal Phase III with FibrocapsTM and Successfully Concludes Safety Review Assessment
Company firmly on track for 2013 regulatory filings in US and Europe
Leiden, The Netherlands and Seattle, WA, November 8, 2012 - ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced that the company has enrolled already more than half of the patients in...
ProFibrix Enrolls First Patients in Pivotal Phase III Study with FibrocapsTM
Lead product on track for market launch in 2014
Leiden, The Netherlands and Seattle, WA, June 6, 2012 - ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in...
ProFibrix to Present FibrocapsTM Phase II Data & Progress in Recombinant Fibrinogen Program at International Conferences
Leiden, The Netherlands and Seattle, WA, July 4, 2012 - ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), will present the results of the company’s Fibrocaps Phase II (FC-002) trial, as well as...
Leiden, The Netherlands and Seattle, WA, January 5, 2012 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general...
Leiden, The Netherlands and Seattle, WA, November 15, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted...
Leiden, The Netherlands and Seattle, WA, September 14, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center...
Leiden, The Netherlands and Seattle, WA, May 3, 2011 - ProFibrix B.V., a leader in the development of innovative products that help stop bleeding (hemostasis) after surgery, today announced the successful closing of a series B follow-on financing. In conjunction...
Leiden, The Netherlands and Seattle, WA, March 8, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has initiated a prospective, multi-center Phase II study with its lead product Fibrocaps...
Leiden and Rotterdam, The Netherlands, August 23, 2010 - ProFibrix B.V., a leader in the development of innovative products based on the blood clotting protein fibrinogen today presents the first Phase II data for its lead product Fibrocaps™. Fibrocaps is...
Leiden, The Netherlands and Seattle, WA, June 17, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical...
Leiden, The Netherlands and Seattle, WA, March 11, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat...
Leiden, The Netherlands and Seattle, WA, August 24, 2009 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing...
Leiden, The Netherlands and Seattle, WA, January 7, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted...
Commercial License to Accelerate Development of New Hemostasis Breakthrough Products
Leiden, The Netherlands, January 13 2009 - ProFibrix B.V., today announced that it has concluded a commercial license agreement with Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) for PER.C6®,...
New COO brings financing and product development experience in the US
Leiden, The Netherlands, September 17 2008: ProFibrix B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, today announced that it has added Jan Ohrstrom,...
Leiden, The Netherlands, 26 March 2007. ProFibrix B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, today announced that it has closed a Series A financing raising $ 11 Million . The round was...
